Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017.

ABSTRACT:

Background

Plasmodium vivax is the predominant Plasmodium species in Afghanistan. National guidelines recommend the combination of chloroquine and primaquine (CQ-PQ) for radical treatment of P. vivax malaria. Artesunate in combination with the antifolates sulfadoxine-pyrimethamine (SP) has been first-line treatment for uncomplicated falciparum malaria until 2016. Although SP has been the recommended treatment for falciparum and not vivax malaria, exposure of the P. vivax parasite population to SP might still have been quite extensive because of community based management of malaria. The change in the P. vivax antifolate resistance markers between 2007 and 2017 were investigated.

Methods

Dried blood spots were collected (n = 185) from confirmed P. vivax patients in five malar

SUBMITTER: Rakmark K 

PROVIDER: S-EPMC7362531 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature